EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain

Paul Healy, Karel Allegaert, Oscar Della Pasqua iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1111/bcp.16201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Paul Healy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Therapeutics Group, University College London, London, UK. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Tramadol, Analgesics, Opioid, Octamer Transcription Factor-1. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Seventh Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Our investigation aimed to assess the dose rationale of tramadol in paediatric patients considering the effect of CYP2D6/OCT1 polymorphisms on systemic exposure. Recommendations were made for the oral dose of tramadol to be used in a prospective study in children (3 months to < 18 years old) with chronic pain.

Methods

Intravenous pharmacokinetic and genotype data from neonatal patients ( n = 46) were available for this analysis. The time course of tramadol and O‐desmethyltramadol (M1) concentrations was characterized using a nonlinear mixed effects approach in conjunction with extrapolation principles. Clinical trial simulations were then implemented to explore the effects of polymorphism, maturation and developmental growth on the disposition of tramadol and M1. Reported efficacious exposure range in adult subjects were used as reference.

Results

The pharmacokinetics of tramadol and M1 was characterized by a two‐compartment model. The total clearance of tramadol (CLPP) comprised CYP2D6‐mediated metabolism (CLPM) and other pathways (CLPO). Age‐related changes in CLPM, CLPO and M1 clearance (CLMO) were described by a sigmoid function, with CYP2D6 as a covariate on CLPP and CLPM, and OCT1 on CLMO. Simulation scenarios including different CYP2D6/OCT1 combinations revealed that steady‐state concentrations are above the putative ranges for analgesia in >15% and >70% of subjects after doses of 3 and 8 mg/kg, respectively.

Conclusions

In the absence of genotyping, reference exposure ranges can be used to define the dose rationale for tramadol in paediatric chronic pain. However, a starting dose of 0.5 mg/kg/day should be considered, followed by stepwise titration to the desired analgesic response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2D6TramadolAnalgesics, OpioidOctamer Transcription Factor-1Chronic PainHumansChildChild, PreschoolInfantFemaleMaleAdolescentProspective StudiesModels, BiologicalPolymorphism, GeneticGenotypeInfant, NewbornDose-Response Relationship, DrugAdministration, Oral

Stichwörter der Autor:innen

CYP2D6OCT1chronic paindose rationaleextrapolationpaediatricstramadol

Substanzen

Cytochrome P-450 CYP2D6TramadolAnalgesics, OpioidOctamer Transcription Factor-1POU2F1 protein, humanO-demethyltramadol

Autor:innen und Institutionen

  • Clinical Pharmacology & Therapeutics Group, University College London, London, UK.
  • Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Department of Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands.
  • Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, London, UK.

ORCID-Profile: Oscar Della Pasqua

Förderung

  • European Union's Seventh Framework Programme

Zitieren

APA

Healy, P., Allegaert, K., & Della Pasqua, O. (2025). Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16201

Vancouver

Healy P, Allegaert K, Della Pasqua O. Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16201

BibTeX
@article{Healy2025,
  author = {Healy, Paul and Allegaert, Karel and Della Pasqua, Oscar},
  title = {Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/bcp.16201}
}
Kostenlos starten →